Argenx
ARGX
#454
Rank
โ‚ฌ47.98 B
Marketcap
766,97ย โ‚ฌ
Share price
3.37%
Change (1 day)
59.03%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): 13,81ย โ‚ฌ

According to Argenx 's latest financial reports the company's current EPS (TTM) is 13,86ย โ‚ฌ. In 2025 the company made an earnings per share (EPS) of 18,48ย โ‚ฌ an increase over its 2024 EPS that were of 12,21ย โ‚ฌ.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)13,81ย โ‚ฌ-25.27%
202518,48ย โ‚ฌ51.44%
202412,21ย โ‚ฌ-369.77%
2023-4,52ย โ‚ฌ-60.46%
2022-11,44ย โ‚ฌ63.33%
2021-7,01ย โ‚ฌ-40.37%
2020-11,75ย โ‚ฌ183.47%
2019-4,14ย โ‚ฌ123.09%
2018-1,86ย โ‚ฌ54.93%
2017-1,20ย โ‚ฌ14.07%
2016-1,05ย โ‚ฌ13.05%
2015-0,93ย โ‚ฌ-36.34%
2014-1,46ย โ‚ฌ209.04%
2013-0,47ย โ‚ฌ-33.99%
2012-0,72ย โ‚ฌ185.59%
2011-0,25ย โ‚ฌ